1.50p+0.05 (+3.45%)31 Dec 2024, 12:45
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Oxford Biodynamics PLC Fundamentals

Company NameOxford Biodynamics PLCLast Updated2024-12-31
IndustryBiotechnologySectorHealthcare
Shares in Issue316.577 mMarket Cap£4.75 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.07EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.5427Debt Equity Ratio3.1843
Asset Equity Ratio6.8224Cash Equity Ratio0.7318
Quick Ratio0.6156Current Ratio0.68
Price To Book Value2.9274ROCE0

Oxford Biodynamics PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Oxford Biodynamics PLC Company Financials

Assets20232022
Tangible Assets£7.00 m£6.98 m
Intangible Assets£1.91 m£1.60 m
Investments00
Total Fixed Assets£8.96 m£8.58 m
Stocks£274,000.00£337,000.00
Debtors£957,000.00£509,000.00
Cash & Equivalents£5.25 m£999,000.00
Other Assets00
Total Assets£16.13 m£11.34 m
Liabilities20232022
Creditors within 1 year£4.00 m£2.91 m
Creditors after 1 year£6.07 m£5.84 m
Other Liabilities00
Total Liabilities£10.07 m£8.76 m
Net assets£6.05 m£2.59 m
Equity20232022
Called up share capital£2.02 m£1.00 m
Share Premium£32.14 m£19.02 m
Profit / Loss-£11.41 m-£7.57 m
Other Equity£6.05 m£2.59 m
Preference & Minorities00
Total Capital Employed£6.05 m£2.59 m
Ratios20232022
Debt Ratio£0.48£0.68
Debt-to-Equity£0.93£2.09
Assets / Equity6.82246.8224
Cash / Equity0.73180.7318
EPS-£0.07-£0.08
Cash Flow20232022
Cash from operating activities-£8.29 m-£5.18 m
Cashflow before financing£4.91 m-£2.62 m
Increase in Cash£4.29 m-£1.36 m
Income20232022
Turnover£510,000.00£154,000.00
Cost of sales£244,000.00£38,000.00
Gross Profit£266,000.00£116,000.00
Operating Profit-£10.17 m-£8.60 m
Pre-Tax profit-£11.41 m-£7.57 m

Oxford Biodynamics PLC Company Background

SectorHealthcare
ActivitiesOxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.
Latest Interim Date18 Jun 2024
Latest Fiscal Year End Date17 Jan 2024

Oxford Biodynamics PLC Directors

AppointedNamePosition
2019-03-13Mr. David Jefferys WilliamsNon-Executive Director,Chairman
2024-12-31Dr. David Mark Anthony HolbrookNon-Executive Director
2020-12-30Mr. Christian Gurth Hoyer Millar Executive Director
2024-12-31Dr. Alexandre Akoulitchev Executive Director,Chief Scientific Officer
2024-04-10Mr. Stephen Charles Diggle Non-Executive Director
2024-12-31Mr. Paul Leslie StockdaleExecutive Director,Chief Financial Officer
2020-12-14Mr. Peter Pack Non-Executive Director,Chairman
2024-12-16Dr. Jon Anthony Joseph BurrowsExecutive Director,Group Chief Executive Officer
2024-12-31Mr. Matthew Anthony WakefieldNon-Executive Director,Chairman

Oxford Biodynamics PLC Contact Details

Company NameOxford BioDynamics PLC
Address26 Beaumont Street, Oxford, OX1 2NP
Telephone+44 1865518910
Websitehttps://www.oxfordbiodynamics.com

Oxford Biodynamics PLC Advisors

StockbrokerShore Capital Stockbrokers Ltd
Phone+44 2074084050
Fax+44 2074084091
BankHSBC Bank PLC
SolicitorMayer Brown International LLP
Phone+44 2031303000
Fax+44 2031303001
AuditorKPMG
Phone+44 1189642000
Fax+44 1189642222
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Financial PR AdviserFTI Consulting Inc
Phone+44 2037271000
Fax+44 2037271007
Nominated AdviserStifel Nicolaus Europe Ltd
Phone+44 2077107600
Fax+44 2077107609
StockbrokerStifel Nicolaus Europe Ltd
Phone+44 2077107600
Fax+44 2077107609
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700